Paul Glaucoma Implant

This intervention is indicated for glaucoma uncontrolled by medical therapy and for patients where prior surgery has proven ineffective, including but not limited to: neovascular glaucoma, pseudoglaucoma, congenital glaucoma, secondary glaucoma stemming from uveitis or epithelial hypoplasia, and individuals experiencing failure of conventional surgical procedures.

The Paul glaucoma implant primarily comprises a plate and a tube, with an adhesive layer situated between the tube's exterior and the ridge groove's interior. Its plate boasts a surface area of 342.1mm². Strategically placed window holes within the plate enable fiber insertion and secure fixation to the eye. The tube effectively channels aqueous humor from the anterior chamber to the eye's exterior, while the adhesive securely bonds the tube within the plate's ridge groove.

**Working Principle:** The Paul glaucoma implant functions by maintaining the patency of the surgical drainage opening, preventing healing and closure to enhance glaucoma surgery outcomes. Most implants incorporate a fluid-conducting tube; the remaining solid structure facilitates aqueous outflow along the implant surface. Regardless of design, all implants share a common objective: reducing intraocular pressure (IOP) by augmenting aqueous humor drainage.

Glaucoma implants trace their evolution to the Molteno implant, first trialed in 1969. Following the China-approved Ahmed glaucoma implant, numerous other designs have emerged.